MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock-At The...
$11,767K
Proceeds from issuance of
common stock-Standby...
$2,348K
Proceeds from stock
option exercise
$32K
Net cash provided by
financing activities
$14,120K
Effect of exchange rate
changes on cash and cash...
$121K
Canceled cashflow
$27K
Net decrease in cash
and cash...
-$5,877K
Canceled cashflow
$14,241K
Issuance of shares for
services
$3,467K
Stock-based compensation
expense
$3,104K
Accounts payable
$2,932K
Prepaid expenses
-$580K
Value of shares issued
for sepa...
$440K
Fair value loss from
sepa arrangement
-$388K
Noncash lease expense
$288K
Depreciation of property and
equipment
$70K
Other receivables
-$3K
Other
-$27K
Net cash used in
operating activities
-$20,112K
Canceled cashflow
$11,272K
Net cash used in
investing activities
-$6K
Net loss
-$28,759K
Pancreatic cancer action
network (pancan)...
-$1,682K
Accrued liabilities
-$360K
Operating lease
liabilities
-$293K
Change in fair value of
warrant derivative
-$153K
Unrealized foreign
exchange gains
$137K
Acquisition of property and
equipment
$6K
Back
Back
Cash Flow
source: myfinsight.com
ONCOLYTICS BIOTECH INC (ONCY)
ONCOLYTICS BIOTECH INC (ONCY)